

A novel synthesis of peptide-6-amino-D-luciferin conjugates for detection of peptidase activities

A. Kovács^{a,b,*}, P. Hegyes^b, B. Ózsvári^b, L. G. Puskás^{b,c}, G. K. Tóth^a


^a University of Szeged, Department of Medical Chemistry, Szeged, Hungary
^b AVIDIN Biotechnology Ltd., Szeged, Hungary
^c AVICOR Ltd., Szeged, Hungary
 *kovacs.anita@med.u-szeged.hu

Biological application

In vivo bioluminescence imaging has become a cornerstone technology for preclinical molecular imaging. This imaging method is based on light-emitting enzymes, luciferases, which require specific substrates for light production. When linked to a specific biological process in an animal model of human biology or disease, the enzyme-substrate interactions become biological indicators that can be studied noninvasively in living animals [1].

Aminoluciferin (*aLuc*) is american firefly (*Photinus pyralis*) luciferin with its 6-position hydroxyl group substituted with an amino group. This modification allows *aLuc* to form amide bond with a peptide, while at the same time retaining the transport and bioluminescent properties of luciferin, resulting in a molecule called peptide-aminoluciferin. Many, partially protected peptide-aminoluciferin (e.g. *Z-Asp-Glu-Val-Asp-aLuc*, *Z-Leu-Glu-His-Asp-aLuc*, *Suc-Leu-Leu-Val-Tyr-aLuc*) are good substrates for bioluminescence assays, for example in the detection of protease activity. Proteases represent important pharmaceutical targets because of their involvement in numerous disease processes [2]. The above mentioned conjugates generally offer significant advantages, such as increased sensitivity, ease of use, and high throughput screening capacity. Luciferase-based assays are typically 10- to 100-fold more sensitive than comparable fluorescent assays (Rhodamine 110, AMC and AFC) [3].

Light emission of the peptide-aminoluciferin








Synthetic problems

The synthesis of different type peptide-6-amino-D-luciferin conjugates and their precursors have been published [2] and some of them are commercially available. However, because of their high price the *in vivo* application of these conjugates is limited. To solve this problem we successfully worked out a new, easier and more convenient and economical method for the preparing these derivatives starting from 2-chloro-benzothiazole. Moreover this products have excellent purity (>99%) and adequate yield (82-93%).

References

- [1] *Biochemistry*, **2006**, *45*, 11103-11112.; [2] *J. of Biomol. Sc.*, **2005**, *10*(2), 137-148.
- [3] *BioTechniques*, **2011**, *51*(2), 105-110.


Synthesis



Acknowledgement

We are grateful for financial support from the grants of GOP-1.3.1-11/B-2011-0002, GOP-1.3.1-11/C-2011-0027, GOP-1.1.1-11-2012-0060 and TAMOP 4.2.2/B-10/1-2012-0012.

Biological tests



In vivo:
 Immunosuppressed SCID mice injected with A375Luc melanoma cells + antitumour drug + Z-DEVD-aLuc → the measured luminescence indicate the increased caspase activity

In vitro:
 Primary rat retinal cell culture + toxin (thapsigargin) → measurement of caspase activity

